2016 Conference
    Home
    • 2016 Conference
      • Programme
      • Presentations A-Z
      • Posters A-Z
      • Delegate list
      • Venue
      • Exhibition
    • 2015 Archive
      • Programme
      • Presentations A-Z
      • Posters A-Z
      • Delegate list
      • Venue
      • Exhibition
    • 2014 Archive
      • Programme
      • Presentations A-Z
      • Posters A-Z
      • Delegate list
      • Venue
      • Exhibition
    • 2013 Archive
      • Programme
      • Presentations A-Z
      • Posters A-Z
      • Delegate list
      • Venue
      • Exhibition
    • 2012 Archive
      • Programme
      • Presentations A-Z
      • Posters A-Z
      • Delegate list
      • Venue
      • Accommodation
      • Exhibition
      • Photos
    • 2011 Archive
      • Programme
      • Presentations A-Z
      • Posters A-Z
      • Delegate list
      • Venue
      • Exhibition
      • Photos
    • Archive 2005 - 2010
        About us
        2013 Archive Presentation
        AbstractBiography
        Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial


        Click here to download the presentation (Powerpoint or viewer needed)
        Author(s)

        Peter Hajek, Katie Myers Smith and Hayden McRobbie

        Presenter(s)

        Katie Myers Smith  Research Fellow, Queen Mary, University of London

        Abstract

        Nicotine replacement therapy (NRT) and varenicline are both effective in helping smokers quit. There is growing interest in combining the two treatments to improve treatment outcomes, but no experimental data exist on whether this is efficacious.  This double-blind randomised controlled trial was designed to evaluate whether adding nicotine patches to varenicline improves withdrawal relief and short-term abstinence rates.

        A hundred and seventeen participants seeking help to stop smoking were randomly allocated to varenicline plus placebo patch or varenicline plus nicotine patch (15mg/16 hour). Ratings of urges to smoke and cigarette withdrawal symptoms were collected weekly over 4 weeks post-TQD. The presentation will describe the results of this much anticipated randomised controlled trial.

        Source of funding: Pfizer Ltd.

        Declaration of interest: None

         
        Abstract
        Join our mailing list